Literature DB >> 16462975

Polypill holds promise for people with chronic disease.

Jacqui Wise.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16462975      PMCID： PMC2626497          DOI： /S0042-96862005001200005

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN： 0042-9686            Impact factor:   9.408


× No keyword cloud information.
  12 in total

1.  The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries.

Authors:  Shanti Mendis; Keiko Fukino; Alexandra Cameron; Richard Laing; Anthonio Filipe; Oussama Khatib; Jerzy Leowski; Margaret Ewen
Journal:  Bull World Health Organ       Date:  2007-04       Impact factor: 9.408

Review 2.  Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.

Authors:  Ginés Sanz; Valentin Fuster
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-23

Review 3.  Issues to consider in the pharmaceutical development of a cardiovascular polypill.

Authors:  Antonio Guglietta; Marta Guerrero
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-23

4.  Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction.

Authors:  Kouta Ito; William H Shrank; Jerry Avorn; Amanda R Patrick; Troyen A Brennan; Elliot M Antman; Niteesh K Choudhry
Journal:  Health Serv Res       Date:  2012-09-21       Impact factor: 3.402

Review 5.  Management of NCD in low- and middle-income countries.

Authors:  William Checkley; Hassen Ghannem; Vilma Irazola; Sylvester Kimaiyo; Naomi S Levitt; J Jaime Miranda; Louis Niessen; Dorairaj Prabhakaran; Cristina Rabadán-Diehl; Manuel Ramirez-Zea; Adolfo Rubinstein; Alben Sigamani; Richard Smith; Nikhil Tandon; Yangfeng Wu; Denis Xavier; Lijing L Yan
Journal:  Glob Heart       Date:  2014-12

6.  Prevalence, awareness and risk factors of hypertension in a large cohort of Iranian adult population.

Authors:  Masoud M Malekzadeh; Arash Etemadi; Farin Kamangar; Hooman Khademi; Asieh Golozar; Farhad Islami; Akram Pourshams; Hossein Poustchi; Behrouz Navabakhsh; Mohammad Naemi; Paul D Pharoah; Christian C Abnet; Paul Brennan; Paolo Boffetta; Sanford M Dawsey; Alireza Esteghamati; Reza Malekzadeh
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

7.  How can we achieve global equity in provision of renal replacement therapy?

Authors:  Sarah L White; Steven J Chadban; Stephen Jan; Jeremy R Chapman; Alan Cass
Journal:  Bull World Health Organ       Date:  2008-03       Impact factor: 9.408

8.  Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Márcio Sommer Bittencourt; Michael J Blaha; Ron Blankstein; Matthew Budoff; Jose D Vargas; Roger S Blumenthal; Arthur S Agatston; Khurram Nasir
Journal:  J Am Coll Cardiol       Date:  2013-10-23       Impact factor: 24.094

9.  Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country--the case of Tanzania.

Authors:  Bjarne Robberstad; Yusuf Hemed; Ole F Norheim
Journal:  Cost Eff Resour Alloc       Date:  2007-02-22

10.  Fixed drug combination in hypertension and hyperlipidaemia in the developing world.

Authors:  Y K Seedat
Journal:  Cardiovasc J Afr       Date:  2008 May-Jun       Impact factor: 1.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.